Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant S-1 + oxaliplatin with TME and LLND for resectable rectal cancer
jRCTs021180033Phase 2Completed
- Start
- Nov 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur and oxaliplatin in rectal cancer. Primary endpoint: cumulative local recurrence rate. Started Nov 2015; status: completed.
02
Drugs
tegafuroxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs021180033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180033.